Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Two Evolocumab Drug Products in Healthy Participants
NCT07545226Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of evolocumab in hypercholesterolemia (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity at Day 64, Area Under the Concentration-time Curve from Time 0 to Time of Last Quantifiable Concentration at Day 64 and 1 more. Started Apr 2026; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07545226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545226.